title: Molecular therapies in hepatocellular carcinoma: what can we target?
abstract: Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
authors.affiliation: Division of Transplantation Surgery, Department of Surgery, College of Medicine, University of Kentucky, 800 Rose Street, Room C453, Lexington, KY, 40536-0293, USA.
authors.forename: Roberto
authors.initials: R
authors.lastname: Galuppo
authors.forename: Dinesh
authors.initials: D
authors.lastname: Ramaiah
authors.forename: Oscar Moreno
authors.initials: OM
authors.lastname: Ponte
authors.forename: Roberto
authors.initials: R
authors.lastname: Gedaly
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D020935:MAP Kinase Signaling System; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells; D009389:Neovascularization, Pathologic
chemical_list: D000970:Antineoplastic Agents